Become Affiliate

PepFlow

Download

The Mito Signal

MOTS-c

A 16-amino-acid mitochondria-derived peptide linked to metabolic stress signaling, AMPK biology, exercise adaptation, insulin sensitivity, and muscle-metabolism research.

Anti-agingMuscle performanceMetabolic health
TierD
EvidencePreliminary
SafetyLimited Data
FDA statusNot Approved
Last reviewed August 11, 2026 47 citations How to read these labels

What is MOTS-c?

MOTS-c is encoded within the mitochondrial 12S rRNA region and is one of the best-known mitochondria-derived peptides. Its discovery helped expand the view of mitochondria from power generators to signaling organelles that can send peptide messages to the nucleus and other tissues.[1][6]

The core research theme is metabolic stress adaptation. MOTS-c has been linked with AMPK activation, nuclear gene-expression changes under stress, glucose handling, muscle metabolism, and exercise-related signaling in preclinical and human-association literature.[5][16][10]

Naming is inconsistent across sources: MOTS-c, MOTs-C, and mitochondrial ORF of the 12S rRNA type-c usually refer to the same 16-amino-acid mitochondrial peptide. The mitochondrial origin matters because the peptide is framed as a signaling message from mitochondrial DNA, not a conventional nuclear-encoded hormone.[1][6] For more context, read the MOTS-c calculation walkthrough.

What MOTS-c is investigated for

MOTS-c evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Insulin sensitivity and metabolic health

Injectable

52%Emerging

MOTS-c is a metabolic-homeostasis candidate with a recruiting prediabetes and overweight trial; efficacy cannot be inferred until interventional results are posted.[46][1]

Human evidence

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, but no outcome results are posted.[46][1]

Animal / mechanistic evidence

Preclinical work supports metabolic homeostasis and insulin-resistance biology.[46][1]

Mitochondrial stress adaptation

Injectable

44%Preliminary

Mitochondrial stress-adaptation support is meaningful mechanistically, while clinical translation remains early.[5][6]

Human evidence

Human clinical meaning is not settled, but the pathway is relevant to metabolic-stress research.[5][6]

Animal / mechanistic evidence

MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress.[5][6]

Exercise adaptation and muscle metabolism

Injectable

32%Limited

Exercise-mimetic claims should remain mechanism and model based until exogenous MOTS-c performance trials report outcomes.[16][10]

Human evidence

Controlled human performance outcomes with exogenous MOTS-c have not been established.[12][16]

Animal / mechanistic evidence

Reviews and preclinical studies link MOTS-c with exercise, mitohormesis, muscle-atrophy signaling, and skeletal-muscle mitochondrial bioenergetics.[10][41]

Cardiovascular risk reduction

Injectable

30%Limited

Cardiovascular benefit remains a biomarker and preclinical hypothesis, not an established prevention or treatment claim.[27][17]

Human evidence

Human cardiovascular evidence is limited to observational biomarker and risk-prediction studies rather than MOTS-c treatment trials.[27][30]

Animal / mechanistic evidence

Animal and tissue studies report myocardial-performance, heart-failure, and diabetic-heart signals tied to MOTS-c biology.[14][17][34]

Longevity and age-related decline

Injectable

24%Limited

Longevity positioning should stay mechanistic; the current evidence does not establish MOTS-c as an anti-aging treatment.[9][18]

Human evidence

No controlled human trial shows that exogenous MOTS-c slows aging or improves longevity outcomes.[18][20]

Animal / mechanistic evidence

Mouse and review literature links MOTS-c to age-dependent physical decline, stress-response biology, and age-related disease mechanisms.[9][18][20]

Evidence snapshot

38%

Human evidence

Preliminary

Published human work is mostly association and trial activity rather than posted efficacy outcomes. The Phase 2a metabolic trial is a translation signal, not proof of benefit.[46][16]

48%

Animal / preclinical

Preliminary

Animal and cell studies repeatedly support metabolic homeostasis, insulin resistance, muscle signaling, and stress-response biology. Translation to user-facing outcomes remains the limiting step.[1][10]

66%

Mechanism support

Moderate

Mitochondrial-to-nuclear signaling and AMPK-linked stress responses give MOTS-c a strong mechanistic frame. Mechanism strength does not replace human outcome data.[5][6]

Forms & administration

MOTS-c is mainly discussed as an injectable research-market protocol. Common practical patterns use morning or pre-workout dosing with an 8-12 week metabolic reassessment window.[16][46]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 5-10 mg per dose.[46]

Frequency

Usually taken once daily.[16]

Timing Considerations

Common timing is morning or before a workout.[16]

Cycle Length

Common cycles run 8-12 weeks.[46]

What to expect

Weeks 1-2

Injectable metabolic use may show up first as changes in energy, training tolerance, appetite, or sleep, while body-composition and lab shifts remain slower.[16]

Weeks 4-8

Waist, weight trend, fasting glucose, and training capacity become more meaningful when diet and activity stay consistent.[46]

Weeks 8-12

A full cycle may show whether metabolic markers, body-composition trend, or subjective performance moved together rather than as isolated day-to-day noise.[1][46]

After stopping

Energy and training changes may fade toward baseline after the cycle, while metabolic markers need a later comparison to show whether any change held.[1][46]

Safety profile

Injectable MOTS-c safety is mainly a local-injection, product-quality, immune-response, and metabolic-context question. Long-term mitochondrial-signaling exposure and durable metabolic effects remain unresolved.[42][44][46]

Common side effects

  • Injection-site pain or swelling[45]

Cautions

  • Unapproved injectable quality[45]
  • Metabolic disease context[46][16]

What we don't know

Chronic human safety, immunogenicity, and durable metabolic effects are not established.[16][46]

Who MOTS-c is not for

Route-specific avoid and medical-review notes:

  • Pregnancy or breastfeeding

    Avoid because reproductive and developmental safety have not been established.[46]

  • Active cancer or complex metabolic disease

    Specialist review is warranted because mitochondrial and metabolic signaling can be disease-context dependent.[16]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Glucose-lowering medications

    Glucose-lowering medications can make glucose and insulin-sensitivity changes harder to interpret during injectable MOTS-c use; this is a theoretical metabolic caution.[46]

Pairing notes

How it works

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Its core mechanism is mitonuclear signaling: under metabolic stress, MOTS-c can move into the nucleus and influence gene programs tied to AMPK activity, glucose handling, and cellular stress adaptation.[1][5][6]

That biology makes injectable MOTS-c plausible for metabolic and exercise-adaptation research, but the mechanism is not the same as proven insulin-sensitivity, endurance, or longevity benefit. Human trials still need to show whether systemic exposure produces meaningful outcomes rather than only stress-response signals.[1][16][46]

Research gaps & open questions

What the current literature has not yet settled about MOTS-c:

01

The ongoing Phase 2 program needs to publish results showing whether MOTS-c improves insulin sensitivity in people and how large the effect is.[46]

02

Human studies need to establish the dose, how the body absorbs and clears MOTS-c, and which safety checks are needed; research-market protocols cannot answer these questions.[16]

03

Controlled trials need to show whether MOTS-c actually improves endurance, strength, or recovery in people rather than relying on exercise-related mechanisms.[10][16]

Common questions

What is MOTS-c best known for?

MOTS-c is best known as a mitochondrial-derived peptide studied for metabolic stress signaling, insulin-sensitivity biology, and exercise-adaptation pathways.[1][16]

Is MOTS-c proven for weight loss?

No. Injectable MOTS-c has metabolic rationale and active human trial activity, but posted controlled human weight-loss outcomes are not established.[46]

Is MOTS-c FDA-approved?

No. MOTS-c has no FDA-approved injectable human use, and the July 23, 2026 PCAC discussion is a 503A compounding review, not approval.[42][44]

Myths & misconceptions

Myth

MOTS-c is a proven exercise mimetic in humans.

Reality

The exercise-mimetic idea comes from mechanism and preclinical biology; human performance outcomes remain unproven.[16]

Myth

A recruiting MOTS-c trial proves it works.

Reality

A recruiting trial shows research activity, not benefit. Results need to be posted or published before raising confidence.[46]

History & discovery

MOTS-c was introduced as a mitochondrial-derived peptide encoded by the 12S rRNA region, turning mitochondrial DNA from a genome of energy machinery into a source of signaling peptides.[1][6]

The original Cell Metabolism paper linked MOTS-c to metabolic homeostasis, obesity resistance, and insulin sensitivity in cell and mouse models.[1]

Follow-up work showed MOTS-c can move to the nucleus during metabolic stress and regulate nuclear gene expression, broadening interest beyond simple mitochondrial biology.[5][6]

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, marking active clinical translation without posted efficacy outcomes.[46]

Published research47 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Build consistency around your healthy-aging goals.

Use PepFlow to record your MOTS-c protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00